The immune factor interferon-lambda may be a key driver of lupus nephritis, according to a recent study that showed persistently high levels of the factor were linked to a poor response to treatment. The study, “Interferon (IFN)-λ is a potential mediator in lupus nephritis,” was published in the journal …
Patients with one autoimmune disease should be closely monitored because they may have a higher risk of developing another autoimmune disease according to a study published in the journal Autoimmune Highlights.
A large-scale retrospective study found that patients with systemic lupus erythematosus (SLE) may be twice as likely to develop dementia as others of similar age and sex, a finding that may help to improve their care. The study, “Increased Risk of Dementia in Patients with Systemic Lupus Erythematosus: A Nationwide…
The U.S. Food and Drug Administration (FDA) has granted fast-track status to Neovacs’ vaccine IFNα Kinoid, which is being evaluated as a treatment for systemic lupus erythematosus (SLE). The vaccine is aimed at blocking interferon alpha, or IFNa, a protein linked to lupus. The more IFNa that patients have, the…
The flu vaccine is effective and associated with a lower risk of hospitalization, pneumonia, admission to the intensive care unit, in-hospital dialysis, and death in people with systemic lupus erythematosus (SLE), a study published in the leading scientific journal Scientific Reports suggests.
The Lupus Agencies of New York State (LANYS) recently announced another victory after Gov. Andrew Cuomo signed into the law the Lupus Education and Outreach Bill. The new legislation will bring essential lupus education to the public and to health professionals. The bill was passed unanimously in June by the…
Eye damage, also referred to as retinopathy, caused by systemic lupus erythematosus may be a sign of more severe disease, as patients with lupus retinopathy have kidney damage more often than patients without eye disease. As lupus retinopathy is suggested to reflect damage to small blood vessels throughout the body,…
Those who develop lupus as youngsters have more severe symptoms and a higher chance of an earlier death, according to a new study. The study in the British journal Lupus suggests that since patients with juvenile-onset systemic lupus erythematosus (JSLE) constitute a high-risk group, doctors need to devote extra attention…
The American Autoimmune Related Diseases Association (AARDA) recently announced its latest #AutoimmuneHeroes — its 22 Scientific Advisory Board (SAB) members who, over the past 25 years, have contributed their time and talents to advancing the association and helping it realize its goals of promoting research into lupus and other autoimmune…
A research study has shown the efficacy and safety of the Benlysta (belimumab), used in combination with other standard of care lupus treatments, such as antimalarials (AM), immunosuppressants (IS) and steroids. The findings may contribute to a better understanding of how Benlysta works as an add-on therapy for systemic lupus erythematosus (SLE). The…